China is treating biotechnology as a strategic national capacity. If we’re serious about competing, we need to talk about capital, facilities, clinical infrastructure — and the workforce that makes all of it run.
The statement I’ve been saying and writing about for years is “The biotech, and its workforce, isn’t just another industry – it’s infrastructure.” We eat, sleep and breathe this philosophy across the various biotech ecosystems and clients that BioBuzz supports.
We don’t argue about this anywhere else. Take energy, transportation, telecom, semiconductors or defense for example. Nobody needs to be convinced that a modern economy has to own that capacity or lose it. Biotechnology is the same category of thing. A country’s ability to discover a medicine, translate it into a product, manufacture it at scale and get it to patients is a public health capability, an economic engine and a national security asset all at once.
And infrastructure isn’t only buildings and equipment. It’s capital. Research institutions. Manufacturing capacity. Regulatory expertise. Clinical development capability. Most of all, it’s people.
I got a useful reframe of that argument this week from a Wall Street banker making an economics argument.
The Warning in This Week’s Market Update
In the latest edition of Stifel’s Biopharma Market Update, which he titled Science, Policy and the Public Good, Managing Director Tim Opler put a fairly uncomfortable proposition in front of the industry: “There is no guarantee that the U.S. remains ascendant in the life sciences forever.”
For an industry that has spent a century assuming the United States is the default center of gravity for biomedical innovation, that’s worth sitting with for a minute.
What made the piece land, though, wasn’t the warning about China. It was where Opler pointed the blame. He isn’t arguing that America should wall itself off from Chinese biotechnology. He’s arguing close to the opposite — that if China is getting dramatically better at converting scientific investment into companies and drug candidates, the more useful question is why.
“Our problems are mainly on the home front – not overseas,” he wrote.
That belongs at the center of this conversation, and it mostly isn’t.
The Sentivera Signal
The timing was almost too good. The same week Opler was making that case, Haisco Pharmaceutical Group announced it had licensed a preclinical immunology asset to Sentivera, a brand-new U.S. venture built by ARCH Venture Partners and Population Health Partners — the same pair behind Metsera. The deal carries potential value of more than $1.5 billion, with roughly $75.9 million in upfront and equity consideration and up to $1.46 billion in milestones. Haisco keeps Greater China; Sentivera takes the rest of the world.
Read that structure carefully, because it’s the part that matters. This isn’t a Chinese asset getting licensed into an existing Western pipeline. American venture investors built a Western company around Chinese-origin science.
That’s a meaningful change in how innovation moves through the global ecosystem. For decades the working assumption was that the U.S. generated the foundational science and other markets licensed, manufactured or commercialized it downstream. That flow now runs both ways, and the NewCo model is what it looks like when it does.
Opler thinks the momentum is accelerating, and he wasn’t subtle about it: “Wait another five years and it could get hellish in the biotech kitchen.” He went further, arguing that calling this a Sputnik moment undersells what’s happening.
I’d frame the underlying dynamic more simply. Capital goes where it finds the best combination of compelling science, reasonable valuations, development speed, available talent, efficient clinical infrastructure, manufacturing capability and a credible path to value. If investors can source promising science more efficiently somewhere else, they will. Protectionism doesn’t change that math. Competitiveness does — and competitiveness isn’t a policy. It’s an ecosystem.
China Is Building Capacity While We Debate Competition
China’s approach has increasingly been to treat biotechnology not as an attractive commercial sector but as strategic national capacity.
In December, the National Development and Reform Commission and Ministry of Finance launched the National Venture Capital Guidance Fund with roughly 100 billion yuan — about $14 billion — in central government capital, structured to pull in local governments, state-owned enterprises, financial institutions and private investors toward a total scale near 1 trillion yuan, or roughly $140 billion. Biopharma sits explicitly on the target list alongside integrated circuits, quantum and AI.
The stated philosophy is almost tailor-made for our industry: invest early, invest small, invest long, invest in hard technology. That’s exactly the segment where timelines are longest, risk is highest and conventional capital is hardest to hold.
And it isn’t bureaucrats picking drug programs. The government supplies the capital and the strategic pressure; professional managers make the company-level calls. Opler’s read was direct: “China is being quite thoughtful about its industrial policy in the life sciences.”
The system has real flaws. State-backed capital distorts markets, local governments chase favored industries, big pools of money create bubbles, and political priorities can run over economic discipline. I’m not arguing we should copy it. I’m arguing we should be honest about why parts of it are working.
America’s Translation Gap
We already have one of the greatest scientific engines ever built. NIH funding created an unmatched network of universities, research hospitals and institutes, and the American system is extraordinarily good at producing discovery.
The structural weakness is what happens next. We subsidize basic research heavily, then hand off the expensive middle — translation, company formation, clinical development, commercialization — almost entirely to private capital. “Our system leaves it almost entirely to the private sector to fund translational research,” as Opler put it.
That handoff works fine until venture markets contract. Then it doesn’t. A discovery is just as valuable to society in a downturn as it was in a bull market — the biology hasn’t changed and the patients haven’t gone anywhere — but the capital available to translate it can vanish in a quarter.
The economic argument underneath this is the one I find most persuasive. Biomedical innovation throws off enormous value that the originating company never captures. Patents expire, generics arrive, knowledge diffuses, new companies build on old discoveries, and therapies developed today keep paying dividends for generations. In economic terms it behaves substantially like a public good. And markets reliably underinvest in goods where society captures more value than the investor does.
What If Washington Became an Investor?
Opler’s proposed fix is ambitious. Rather than simply expanding grant funding, he’d create a national life sciences sovereign fund of funds — long-duration public capital deployed through existing venture firms into biotech companies, with a suggested $200 billion authorization over ten years. His shorthand for the model is the most quotable line in the piece: “CPRIT’s balance sheet with Indiana’s allocation discipline, at fifty times the size of either.”
The distinction is structural. Instead of government → grant → research, the model becomes public capital → professional investors → companies → returns. Washington provides patience; professional investors still decide which technologies and teams deserve funding.
Whether $200 billion is the right number, or a sovereign fund is the right vehicle, is exactly the kind of thing economists and policymakers should fight about in public. The bigger question is the one nobody is asking plainly: how much biotechnology capacity does America actually believe it needs?
Once you frame biotech as infrastructure, that question becomes answerable. Until you do, it isn’t even askable.
The Part of the Infrastructure Nobody Funds
Here’s where I’d extend Opler’s argument, because it’s the piece I’ve watched get left out of every version of this conversation for the better part of two decades.
Capital alone doesn’t create an industry. Neither do research grants, tax incentives for new labs, or venture funds. A functioning bioeconomy needs an interconnected system that can repeatedly move ideas from discovery through translation, clinical development, manufacturing and commercialization to patients. People operate every stage of that system.
You can build a $500 million GMP facility. Without the process engineers, manufacturing technicians, automation specialists, quality professionals, validation experts, scientists and skilled tradespeople to run it, what you’ve built is a very expensive building. That workforce isn’t downstream of innovation. It’s a prerequisite for it.
Yet we still file workforce under economic development — a separate program, a separate budget line, a separate conference track from facilities, research and company formation. We call the manufacturing plant infrastructure and the people who operate it workforce development. Why?
Nobody would site a semiconductor fab without knowing where the technicians come from. Nobody expands a shipyard without developing welders and electricians. A region that wants biomanufacturing needs manufacturing technicians. Advanced therapies need specialized process development, quality and regulatory talent. AI-enabled drug development needs people fluent in both emerging technology and regulated environments. Labs and plants need HVAC techs, pipefitters and controls technicians who can work inside highly specialized facilities. Startups need experienced operators and fractional specialists who can get a young company through an inflection point.
None of that gets built the week a company announces 300 new jobs. I’ve watched that timeline collide with reality in the BioHealth Capital Region more times than I can count. It has to exist before the demand arrives — which is precisely what infrastructure investment is for. It builds capacity before you’re desperate for it.
Build the System, Not Just the Buildings
We still hold extraordinary advantages: world-leading universities, NIH, deep capital markets, major pharmaceutical companies, sophisticated regulators, experienced entrepreneurs, an enormous healthcare market and one of the deepest talent pools on earth.
Advantages aren’t permanence. Opler’s history lesson is worth keeping close — leadership in biomedical innovation has migrated before, from Greece and Rome to Persia, Italy, England, France, Germany and eventually here. America has held it for roughly a century. There’s no law that says the next century is ours.
So the right response to China’s rise should be bigger than restriction. It should be investment — not in one company, one building, one university or one technology, but in capacity. Basic science. Translational capital. Biomanufacturing. Clinical infrastructure. Regional innovation ecosystems. And the workforce that makes every one of those investments productive.
At BioBuzz we’ve spent years building the connective tissue for exactly that last piece, because the bioeconomy runs on relationships, trust and community, and because talent moves through a supply chain whether or not anyone is managing it. That’s the work. But the policy point stands on its own without us in it.
The real competition was never about which country invents the next drug. It’s about which country builds the ecosystem capable of producing the next hundred drugs, the next thousand companies and the next generation of breakthroughs.
That’s infrastructure. And if biotechnology is infrastructure, then the people who make biotechnology possible are infrastructure too.
